Novel therapies for an old virus: treatment of RSV infections in the 21st Century.
Respiratory syncytial virus (RSV) is a pathogen whose existence has been known for decades, causing mild-to-severe upper and lower respiratory tract infections that bear the risk of subsequent asthma and can even lead to a fatal outcome. RSV infects all groups of patients and is a major cause of hospitalization in children and in the elderly. This review briefly summarizes the current status of RSV drug development and clinical trials for drugs available for the treatment of RSV infections.
Lüsebrink
Jessica
J
Institute of Virology, University of Bonn Medical Centre, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.
Schildgen
Verena
V
Schildgen
Oliver
O
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006025:Glycosaminoglycans / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D034741:RNA, Small Interfering / Q000627:therapeutic use; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects*; D014760:Viral Fusion Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D053585:Virus Attachment / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D001562:Benzimidazoles; D006025:Glycosaminoglycans; D018950:Lipopolysaccharide Receptors; D034741:RNA, Small Interfering; D014760:Viral Fusion Proteins